ERBB2 and non-small cell lung carcinoma: The efficacy of TKIs in NSCLC treatment may depend on HER2 mutation subtypes [12, 13, 14]; however, no significant differences in pyrotinib effectiveness were found between patients with HER2 ex20ins and non‐ex20ins mutations.